Table 1.
Demographic and medical data of the sample
| Breast cancer patients (N = 92) | Prostate cancer patients (N = 46) | |||||
|---|---|---|---|---|---|---|
| Treatment group (N = 68) | Control group (N = 24) |
p | Treatment group (N = 25) | Control group (N = 21) |
p | |
| Patient demographics | ||||||
| Age (years) | ||||||
| Mean (SD) | 54.3 (10) | 52.5 (6.8) | .535 | 64.11 (5.8) | 65.7 (4.4) | .330 |
| Range | 29–72 | 39–65 | 47–73 | 58–75 | ||
| Cultural origin, N (%) | ||||||
| Occidental Europe | 66 (97.0) | 0 | NAa | 25 (100) | 21 (100) | NAa |
| Near and Middle East | 1 (1.5) | 0 | 0 | 0 | ||
| African | 1 (1.5) | 0 | 0 | 0 | ||
| Missing data | 0 | 24 (100) | 0 | 0 | ||
| Marital status, N (%) | ||||||
| Single | 5 (7.4) | 1 (4.1) | .778 | 1 (4.0) | 0 | .544 |
| Married/living with partner | 52 (76.5) | 18 (75) | 20 (80.0) | 16 (76.2) | ||
| Divorced/separated/widowed | 11 (16.2) | 5 (20.8) | 4 (16.0) | 5 (23.8) | ||
| Missing data | 0 | 0 | 0 | 0 | ||
| Education level, N (%) | ||||||
| Elementary school or less | 0 | 3 (12.5) | .001 | 1 (4.00) | 2 (9.5) | .557 |
| Lower secondary school | 8 (11.8) | 7 (29.2) | 1 (4.00) | 4 (19.0) | ||
| Upper secondary school | 21 (30.9) | 8 (33.3) | 7 (28.00) | 5 (23.8) | ||
| Bachelor’s degree | 6 (8.8) | 4 (16.7) | 3 (12.00) | 1 (4.8) | ||
| Master’s degree | 29 (42.6) | 2 (8.3) | 12 (48.00) | 8 (38.1) | ||
| Post-graduate | 4 (5.9) | 0 | 1 (4.00) | 1 (4.8) | ||
| Missing data | 0 | 0 | 0 | 0 | ||
| Employment status, N (%) | ||||||
| Employed part or full time | 9 (13.2) | 8 (33.3) | .080 | 8 (32.00) | 4 (19.0) | .344 |
| Employed, taken time off | 38 (55.9) | 12 (50) | 2 (8.00) | 3 (14.3) | ||
| Not employed | 20 (29.4) | 4 (16.7) | 15 (60.00) | 14 (66.7) | ||
| Missing data | 1 (1.5) | 0 | 0 | 0 | ||
| Patient medical history | ||||||
| Time since diagnosis (months) | ||||||
| Mean (SD) | 7.1 (5.1) | 5.8 (5.0) | .368 | 6.16 (3.52) | 6.00 (4.3) | .894 |
| Range | 1–27 | 0.5–19 | 1–15 | 2–22 | ||
| Cancer stage, N (%) | ||||||
| 0 | 1 (1.5) | 3 (12.5) | 0 | 0 | ||
| 1 | 37 (54.4) | 13 (54.2) | 0 | 0 | ||
| 2 | 22 (32.4) | 3 (12.5) | .022 | 0 | 0 | |
| 3 | 5 (7.4) | 0 | 0 | 0 | ||
| Missing data | 3 (4.4) | 5 (20.8) | 25b | 21b | ||
| Surgery, N (%) | ||||||
| Yes | 68 (100) | 23 (95.8) | NAa | 25 (100) | 21 (100) | NAa |
| No | 0 | 0 | 0 | 0 | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Chemotherapy (CT), N (%) | ||||||
| CT completed | 27 (39.7) | 7 (29.2) | .727 | 0 | 0 | NAa |
| During CT | 20 (29.4) | 8 (33.3) | 0 | 0 | ||
| No CT | 21 (30.9) | 8 (33.3) | 25 (100) | 21 (100) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Radiation therapy (RT), N (%) | ||||||
| RT completed | 30 (44.1) | 6 (25) | .280 | 1 (4.0) | 0 | .354 |
| During RT | 6 (8.8) | 2 (8.3) | 0 | 0 | ||
| Not yet started | 16 (23.5) | 10 (41.7) | 0 | 0 | ||
| No RT | 16 (23.5) | 5 (20.8) | 24 (96.0) | 21 (100) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
| Hormonal therapy (HT), N (%) | ||||||
| During HT | 38 (55.9) | 8 (33.3) | .209 | 2 (8.0) | 1 (4.8) | .658 |
| Not yet started | 23 (33.8) | 11 (45.8) | 0 | 0 | ||
| No HT | 7 (10.3) | 4 (16.7) | 23 (92.0) | 20 (95.2) | ||
| Missing data | 0 | 1 (4.2) | 0 | 0 | ||
Bold values indicate significant difference (p < .05)
aNA (Not applicable) when missing data impeded the analysis, or when the two groups are exactly equivalent (p = 1)
bAll prostate cancer patients were recruited after their surgery and none had metastases